+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
EUSA Pharma Ltd - logo

Founded in 2006, EUSA Pharma is a specialty pharmaceutical company that focuses on oncology and oncology supportive care, as well as pain control and critical care products. The company’s products include Caphosol for the treatment of oral mucositis; ProstaScint for imaging the extent and spread of prostate cancer; Quadramet for the treatment of pain in patients and a variety of others. The company is based in Langhorne, Pennsylvania. EUSA Pharma operates as a subsidiary of Essex Bidco Ltd.

Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020 - Product Thumbnail Image

Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020

  • Report
  • June 2020
  • 500 Pages
From
Fotivda (tivozanib; AVEO Oncology/EUSA Pharma/Kyowa Hakko Kirin) Drug Overview 2019 - Product Thumbnail Image

Fotivda (tivozanib; AVEO Oncology/EUSA Pharma/Kyowa Hakko Kirin) Drug Overview 2019

  • Report
  • March 2019
  • 16 Pages
Neuroblastoma - Pipeline Review, H1 2020 - Product Thumbnail Image

Neuroblastoma - Pipeline Review, H1 2020

  • Drug Pipelines
  • May 2020
  • 915 Pages
From
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2020 - Product Thumbnail Image

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2020

  • Report
  • April 2020
  • 400 Pages
From
Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2020 - Product Thumbnail Image

Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2020

  • Report
  • April 2020
  • 2000 Pages
From
Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2020 - Product Thumbnail Image

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2020

  • Report
  • April 2020
  • 2500 Pages
From
Global Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2020 - Product Thumbnail Image

Global Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2020

  • Report
  • April 2020
  • 600 Pages
From
Global Genetic Disorders Partnering 2014-2020: Deal trends, players and financials - Product Thumbnail Image

Global Genetic Disorders Partnering 2014-2020: Deal trends, players and financials

  • Report
  • June 2020
  • 350 Pages
From
Global Specialty Pharmaceutical Partnering Terms and Agreements 2014-2020: Deal Trends, Players and Financials - Product Thumbnail Image

Global Specialty Pharmaceutical Partnering Terms and Agreements 2014-2020: Deal Trends, Players and Financials

  • Report
  • March 2020
  • 600 Pages
From
Global Big Pharma Partnering Terms and Agreements 2014-2020: Deal Trends, Players and Financials - Product Thumbnail Image

Global Big Pharma Partnering Terms and Agreements 2014-2020: Deal Trends, Players and Financials

  • Report
  • March 2020
  • 1800 Pages
From
Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019 - Product Thumbnail Image

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 2062 Pages
From
Neuroblastoma - Market Insights, Epidemiology and Market Forecast-2027 - Product Thumbnail Image

Neuroblastoma - Market Insights, Epidemiology and Market Forecast-2027

  • Drug Pipelines
  • April 2018
  • 128 Pages
From
Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 - Product Thumbnail Image

Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020

  • Report
  • March 2020
  • 1300 Pages
From
Oral Mucositis (OM) - Market Insights, Epidemiology and Market Forecast-2027 - Product Thumbnail Image

Oral Mucositis (OM) - Market Insights, Epidemiology and Market Forecast-2027

  • Drug Pipelines
  • October 2018
  • 120 Pages
From
2018 Post-ASCO Report - Product Thumbnail Image

2018 Post-ASCO Report

  • Report
  • June 2018
  • 150 Pages
From
The ROI of Orphan Drugs-- Ensuring optimal returns (2017) - Product Thumbnail Image

The ROI of Orphan Drugs-- Ensuring optimal returns (2017)

  • Report
  • December 2017
From
  • 16 Results (Page 1 of 1)
Loading Indicator
adroll